Pharvaris (NASDAQ:PHVS – Get Free Report)‘s stock had its “overweight” rating reiterated by investment analysts at Morgan Stanley in a research report issued to clients and investors on Monday, Benzinga reports. They presently have a $34.00 price target on the stock. Morgan Stanley’s price objective indicates a potential upside of 64.65% from the stock’s previous […]
JMP Securities reissued their market outperform rating on shares of Pharvaris (NASDAQ:PHVS – Free Report) in a research note released on Wednesday, Benzinga reports. JMP Securities currently has a $49.00 price target on the stock. Several other equities analysts also recently issued reports on the stock. Wedbush decreased their price objective on shares of Pharvaris […]
ZUG, Switzerland , Feb. 16, 2024 (GLOBE NEWSWIRE) Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the extraordinary general meeting of shareholders will take place on Wednesday, March 6, 2024, at 12:00 CST (6:00 a.m. EST). All relevant documents and information relating to the extraordinary general meeting, including the notice and agenda for the extraordinary
Pharvaris (NASDAQ:PHVS – Free Report) had its price target hoisted by JMP Securities from $40.00 to $49.00 in a research report released on Tuesday, Benzinga reports. JMP Securities currently has a market outperform rating on the stock. Other analysts also recently issued research reports about the stock. Wedbush decreased their price target on shares of […]
Pharvaris (NASDAQ:PHVS – Get Free Report) had its price objective increased by equities research analysts at JMP Securities from $40.00 to $49.00 in a research note issued to investors on Tuesday, Benzinga reports. The firm currently has a “market outperform” rating on the stock. JMP Securities’ price target indicates a potential upside of 68.97% from […]